Our skin printing technology based on the use of 3D bio printers and patented bio active inks is in development and have obtained succesful pre-clinical results.
Printed skin for drug, cosmetic, sanitary and chemical consumer product testing ready for final production and marketing.
Large-scale allogeneic skin printing. Successful pre-clinical studies already completed.
Use of patented bio inks approved for animal testing. Ready for EU approval
Industrial design according to EU (CE) regulations
Successful pre-clinical phase already complete
Technique uses the same patented bio inks already approved by the AEMPS
Requires GMP manufacture process approval for inks and final skin as well as EMA approval through a centralized clinical trial (phase II/III)